FDA
-
-
-
-
-
-
-
Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
-
-
-
-
-
-
-
Ligand Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Verona Pharma to Present at Jefferies Healthcare Conference
-
-
-
-
-
-
-
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
-
-
-
-
-
-
-
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
-
-
-
-
-
-
-
Franciosi Consulting Reviewing the Use of Psilocybin for Treating Depression, Anxiety and Addiction
-
-
-
-
-
-
-
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
251,639 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All